Antimicrobial activity of N-chloramine compounds

Kohl, Herbert H.; Wheatley, W. B.; Worley, S. D.; Bodor, Nicholas

doi:10.1002/jps.2600691116

Cited by 32 publications

(21 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…141 Monochloramine was also found to react directly with DNA during the inactivation of vegetative B. subtilis. U2 The organic halamine 3-chloro-4,4-dimethyl-2-oxazolidinone (compound I) was found in the laboratories of the authors to react with sulfhydryl-containing enzymes in in vitro reactions 115116 and to preferentially inhibit DNA synthesis of E. coli 115 and S. aureus. 52 In addition to DNA synthesis, RNA and protein syntheses were also inhibited by the oxazolidinone, but at higher concentrations of disinfectant.…”

Section: Mode Of Disinfectant Actionmentioning

confidence: 99%

Halamine water disinfectants

Worley

Williams

Crawford

1988

Critical Reviews in Environmental Control

184

199

View full text Add to dashboard Cite

Section: Mode Of Disinfectant Actionmentioning

confidence: 99%

Halamine water disinfectants

Worley

Williams

Crawford

1988

Critical Reviews in Environmental Control

184

199

View full text Add to dashboard Cite

“…It is exceptionally stable in water and in dry storage [390,391]; it is nontoxic in chicken's drinking water at 200 mg/L, and it detoxifies aflatoxin [392]. The mechanism of action of these compounds involves inhibition of bacterial growth by inhibiting DNA, RNA, and protein synthesis [393]. When the chlorine interacts with -SH containing enzymes, the original precursor is regenerated.…”

Section: Activated Soft Drugsmentioning

confidence: 99%

Retrometabolism‐Based Drug Design and Targeting

Bodor

Buchwald

2010

Burger's Medicinal Chemistry and Drug Discovery

View full text Add to dashboard Cite

Retrometabolic drug design (RMDD) approaches are systematic methodologies aimed to design safe compounds with an improved therapeutic index. RMDDs thoroughly integrate structure– activity and structure‐metabolism considerations into the entire design process and incorporate two major concepts aimed to design soft drugs and chemical delivery systems, respectively. Soft drugs (SDs) are new, active therapeutic agents designed to undergo predictable metabolism resulting in inactive metabolites after exerting their desired therapeutic effect(s). Chemical delivery systems (CDSs) are biologically inert molecules that provide enhanced and targeted delivery of an active drug to a particular organ or site through a designed sequential metabolism that involves several steps. Here, we present a comprehensive review including a general overview of the RMDD principles and a large number of specific examples from various pharmacological areas, including many recent developments, to illustrate RMDD concepts. Whenever possible, the rationale for the design as well as the pharmacokinetic and pharmacodynamic properties of the new therapeutic agents are briefly summarized and compared to those of the other compounds used in the same field.

show abstract

“…The cellular mechanisms of action of Agent I in inhibiting bacterial DNA, RNA, and protein synthesis have been addressed in these laboratories in a preliminary manner also (10).…”

Section: List Of Tablesmentioning

confidence: 99%